Pacira BioSciences, Inc. has announced organizational changes at its Science Center Campus, which include the decommissioning of the 45-liter facility that has been manufacturing EXPAREL commercial supply since 2014. This decision is aligned with the company's progress in transitioning to an enhanced, large-scale 200-liter manufacturing process in both San Diego and Swindon. As a result of this change, there has been a reduction in the workforce across the Technical Operations team, impacting approximately 70 colleagues.
The company expressed gratitude for the contributions of the affected individuals, acknowledging their significant role in delivering EXPAREL to more than 16 million patients over the years. While the decision was described as not being made lightly, it indicates a strategic shift in the company's manufacturing processes.
This announcement highlights the company's commitment to maintaining optimal inventory levels to meet the growing demand for EXPAREL, iovera°, and ZILRETTA, despite the impact on the workforce. The leadership team has emphasized its dedication to ensuring that the impacted individuals are treated with dignity and respect.
The company's decision to decommission the 45-liter facility and the subsequent reduction in the workforce demonstrates a significant shift in its manufacturing operations, signaling a focus on enhancing efficiency and meeting the increasing demand for its products. Following these announcements, the company's shares moved -0.04%, and are now trading at a price of $23.17. If you want to know more, read the company's complete 8-K report here.
